What Eli Lilly and Novo Nordisk’s earnings reveal about the future of GLP-1 sales

It was an exciting, if sometimes uncertain, year for the GLP-1 business. Just take a look at the past week. On Wednesday, Novo Nordisk (NVO) missed Wall Street estimates for second-quarter GLP-1 sales, citing ongoing supply shortages of weight-loss drug…